The donor egg IVF treatment market is set to reach US$ 3,676.8 Mn by 2027 from US$ 1,782.1 Mn in 2018 highlighting moderate growth at a compounded annual growth rate (CAGR) of 8.4% during the forecast period from 2019 to 2027. In the last 2 decades there has been a paradigm shift observed in the society which has major influence over the consistently growing infertility rate. Significant rise in working women, delayed marriages, advanced maternal age etc provide a positive impetus for the donor egg IVF treatment market.
Market Synopsis
Get a sample copy for more information
"High success rate associated with pregnancy and efficiency in retrieving viable embryos derive the fresh donor egg IVF cycle market"
Fresh donor egg IVF cycle is reigning the cycle type segment for donor egg IVF treatment market. The advantages associated with fresh donor egg IVF treatment cycle are high success rate associated with pregnancy and efficient method to retrieve viable embryos. The limitation associated with this cycle type is long waiting period. Frozen donor egg IVF cycle market are gaining traction on account of effective screening, consistent cohorts ready to be shipped, thawed and used as per clients schedule. Change in lifestyle and family planning motivate people to freeze eggs for future children and siblings.
Get a sample copy for more information
"Technological advancement in IVF treatment protocols and state of the art capital equipments drive the fertility clinics market growth"
Fertility clinics are dominating the end user segment for donor egg IVF treatment market. Inherent features such as technological advancement in IVF treatment protocols such as egg freezing, hatching, vitrification, gamete intrafallopian transfer (GIFT) etc. provide the necessary impetus for the market growth of fertility clinics worldwide. Healthcare agencies in developed countries are providing huge financial aid to establish IVF treatment centers in hospitals to cater services to people in remote areas
Get a sample copy for more information
"Rising prevalence of menopause and increasing public health awareness related to infertility drive the market growth in North America region"
North America with a market share of 34% is the leading regional segment for donor egg IVF treatment market. The paramount factors responsible for its dominance are rising prevalence of menopause. As per the statistics provided by American Congress of Obstetricians and Gynecologists approximately 2 million women reach early menopause annually. Increasing public health awareness related to infertility will propel the market growth in the region. Europe accounts for 32% market share owing to change in lifestyle prioritizing professional career over personal life, and hence opting for late stage pregnancy induced via IVF treatment. Asia Pacific is representing 24% market growth on account of significant rise in fertility clinics and increasing fertility tourism as IVF treatment is available at affordable price.
Historical & Forecast Period
This research report presents the analysis of each segment from 2017 to 2027 considering 2018 as the base year for the research. Compounded annual growth rate (CAGR) for each respective segments are calculated for the forecast period from 2019 to 2027.
The market segmentation for the scope of report is done as by cycle type, end user and geography.
ATTRIBUTE | DETAILS |
---|---|
Research Period | 2017-2027 |
Base Year | 2018 |
Forecast Period | 2019-2027 |
Historical Year | 2017 |
Unit | USD Million |
Segmentation |
By Cycle Type (2017–2027; US$ Mn) |
By End User (2017–2027; US$ Mn) |
|
Geography Segment (2017–2027; US$ Mn) |
Pharmaceutical companies specializing in providing IVF treatment services are Cook Medical, Inc., EMD Serono, Inc., Flinders Reproductive Medicine Pty. Ltd., Fertility First, Genea Oxford Fertility Limited, OvaScience, Procrea Fertility, Progyny, Inc., ReproMed and Vitrolife AB.